Related Experiment Video
Updated: May 29, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
Standard Clinical Characteristics Fail to Predict Mild Chemotherapy-induced Peripheral Neuropathy in Breast Cancer
Dirk Rades1,2, Maria K Streubel2, Christian Staackmann2
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; dirk.rades@uksh.de.
Anticancer Research
|May 27, 2026
Summary
This study found no clinical risk factors for chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients. Early diagnosis of CIPN remains challenging, highlighting the need for vigilant monitoring during taxane therapy.
Area of Science:
- Oncology
- Pharmacology
- Neurology
Background:
- Taxane-based chemotherapy is a common treatment for breast cancer.
- Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of taxane therapy.
- Limited treatment options for CIPN necessitate early diagnosis and risk factor identification.
Purpose of the Study:
- To identify clinical risk factors associated with mild CIPN in breast cancer patients undergoing taxane chemotherapy.
- To contribute to the early diagnosis of CIPN by understanding predictive patient and chemotherapy characteristics.
Main Methods:
- Retrospective study of 96 breast cancer patients, with 48 experiencing mild CIPN and 48 without.
- Evaluation of 14 chemotherapy-related and patient-related characteristics.
- Statistical analysis to determine associations between characteristics and mild CIPN.
Main Results:
- No significant associations were found between any of the 14 evaluated clinical characteristics and the development of mild CIPN.
- p-values for all evaluated factors ranged between 0.40 and 1.00, indicating no statistical significance.
Conclusions:
- Standard clinical profiling is insufficient for stratifying breast cancer patients at risk for CIPN.
- Vigilant clinical monitoring during and after taxane-based therapy is essential for managing CIPN.
- Future research should explore novel molecular or genetic biomarkers for CIPN risk assessment rather than relying on clinical tools.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:26Peripheral Artery Disease IV: Nursing Management
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...